Beyond FDA-licensed red cell genotyping and specialization in the RH system, our laboratory provides a comprehensive suite of additional blood group genotyping services designed to support precise transfusion management across diverse clinical needs.
Our Research and Commitment to the Future
We are also committed to advancing the future of blood group genomics through our active participation in the Blood Transfusion Genomics Consortium (BTGC)—a global scientific collaboration shaping next‑generation standards for extended antigen typing, rare variant discovery, and population‑level genomic mapping of blood groups. As contributors to this international effort, we integrate emerging innovations, best practices, and validated technologies into our own testing pipelines, ensuring our clients benefit not just from today’s capabilities, but from the rapidly evolving future of transfusion genomics.
Together, these services position our laboratory at the forefront of comprehensive blood group genotyping—supporting safer transfusions, more precise donor‑patient matching, and broader genomic insight across all major blood group systems.